Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
10 vials of lyophilized powder for injection
The NMCP group had a slightly older average age (55.1 years) compared to the OMCP group (53.1 years)
It even lowers the risk of a heart attack or heart disease if these symptoms and diseases are due to low glutathione levels
By focusing on both medical interventions and lifestyle factors, it provides a more sustainable path to long-term mental wellness
Unlike many other natural compounds, berberine works at the cellular level by activating an enzyme called AMP-activated protein kinase (AMPK)
